Products List
Products
Home > Product List > API >

GF120918 143664-11-3

1.Inquiries will be replied within 24 hours
2.We could supply various packages as you required
3.To protect the profit of our agents, price will not show on website, please send inquiries to get the price.
4.Fast delivery, goods arrive your office within 3 to 5 days
5.Please click "Inquiry" or "Email" below to get the price
　
Synonyms ：
Appearance ：
white powder
Chemical Formula ：
C34H33N3O5
Solubility ：
Molecular Weight ：
563.64
Storage and Stability ：
in stock
CAS No. ：
143664-11-3
Purity ：
99.5%
Introduction
Elacridar is a potent P-glycoprotein (Pgp) and BCRP inhibitor, used for cancer treatment. In Vitro: Elacridar inhibits P-glycoprotein (P-gp) labeling by [3H]azidopine with a IC50 of 0.16 μM. In Caki-1 and ACHN cells, elacridar (2.5 μM) significantly ihibits the cell growth. The P-glycoprotein activity is found to be inhibited by elacridar. The combination of elacridar and sunitinib lead to a significant reduction in ABC Sub-family B Member 2 (ABCG2) expression in 786-O cells. In Vivo: Oral co-administration of elacridar (100 mg/kg, p.o.) and crizotinib increases the plasma and brain concentrations and brain-to-plasma ratios of crizotinib in wild-type mice, equaling the levels in Abcb1a/1b; Abcg2-/- mice. In friend leukemia virus stain B mice, the brain-to-plasm partition coefficient (Kp, brain) of elacridar is 0.82, 0.43, and 4.31 after intravenous (2.5 mg/kg), intraperitoneal (100 mg/kg), and oral (100 mg/kg) treatment, respectively. In Mrp4(-/-) mice, elacridar fully inhibits P-gp mediated transport of topotecan, without siginificant effects on Bcrp1-mediated transport.

Thank you for your company product support!

CAS No. ：

Product Name ：

Number ：

Your name：
*

Phone：

Email：
*

The company or laboratory name：
*